Evidence map›Paper›PMID 31505772›Full record

ArticleAntioxidants (Basel, Switzerland)2019

Side Effects of Curcumin: Epigenetic and Antiproliferative Implications for Normal Dermal Fibroblast and Breast Cancer Cells.

Laura Cianfruglia, Cristina Minnelli, Emiliano Laudadio, Andrea Scirè, Tatiana Armeni

Open access · goldAbstract read
In one paragraph

Article in Antioxidants (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 89 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. A COPharmaceutics · 2023
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Laura CianfrugliaDipartimento di Scienze Cliniche Specialistiche ed Odontostomatologiche-Sez. Biochimica, Biologia e Fisica, Università Politecnica delle Marche, 60131 Ancona, Italy.
Cristina MinnelliDipartimento di Scienze della Vita e dell'Ambiente, Università Politecnica delle Marche, 60131 Ancona, Italy.
Emiliano LaudadioDipartimento S.I.M.A.U., Università Politecnica delle Marche, via Brecce Bianche, 60131 Ancona, Italy.
Andrea ScirèDipartimento di Scienze della Vita e dell'Ambiente, Università Politecnica delle Marche, 60131 Ancona, Italy. a.a.scire@staff.univpm.it.ORCID 0000-0002-8288-6989
Tatiana ArmeniDipartimento di Scienze Cliniche Specialistiche ed Odontostomatologiche-Sez. Biochimica, Biologia e Fisica, Università Politecnica delle Marche, 60131 Ancona, Italy. t.armeni@staff.univpm.it.
Marche Polytechnic University · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCurcumin is a yellow-orange pigment obtained from the plant

methodsWe used cellular viability and growth assays to evaluate the antiproliferative action of curcumin, analyzed the endogenous glutathione levels, conducted cell cycle, apoptosis, and necrosis analyses, and performed immunodetection of glutathionylated and acetylated H3 histones.

resultsWe found that HDFs are more sensitive to curcumin treatment than MCF7 cells, resulting in pronounced arrest of cell cycle progression and higher levels of cellular death. In both cell types, the homeostasis of the redox cellular environment did not change after curcumin treatment; however, significant differences were observed in glutathione (GSH) levels and in S-glutathionylation of H3 histones.

conclusionCurcumin administration can potentially confer benefits, but high doses may be toxic. Thus, its use as a dietary supplement or in cancer therapies has a double edge.

Indexed as

curcuminglutathionehistone glutathionylationhuman cancer cellspost-translational modifications (PTMs)

Identifiers

PMID31505772
PMCPMC6770744
OpenAlexW2972558228

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.